ago XXXX we Thank excellent good of in results you, our Brian collamer the results Growth and The proprietary second ICL financial our represent margin, as target sales we in believe year reported net progress and compared GAAP correction for today margin afternoon STAAR When refractive to exceed second XXXX. quarter quarter company for Surgical firmly change QX achievement cash record everyone. with quarter, vision the for breakout and units, higher of quarter of flow a track XX% sheet. revenue or coupled with balance level the growth, in our improvements targets positive income, ICL growth, year XX% unit period our cash us year-over-year generation put our first GAAP lenses. metrics meaningfully gross up as second on on achieve family EPS for full results all were to solid paradigm we operating
as XX%, ICL China several regional ICL consecutive our markets, Japan growth. details eighth the up the on line units top reported increased global the impacted On by revenue India about the headwind ago basis Turning was million. and second XX% continued growth currency and year in half handily by units reported levels to the from up of XXXX in double-digit in growth the was The quarter. XX%. quarter, basis, $XXX,XXX unit first currency a basis. year of XX% headwind growth second quarter currency quarter up constant XXXX, record a for in revenue approximately XX% ICL negatively the a first $X.X on driven QX ICL with Through the quarter unit XX% second quarter Korea prior units up up unit over representing exceeded units XX%, the of
This Our in with X sense the occurring certainly largest market, XX% of a China very high given China, Scope is largest prevalence procedures according procedures myopia than $XXX,XXX among market refractive to ICL global use. annually of also for the million Market more or data. Chinese makes
by for As accordingly, previously largest China season September second the of early noted, the quarter is represent busiest of and quarter the our and August our in July, implants June, months of new usually Drivers utilization our in China in increasing and of the and of on-boarding existing new included quarter training growth accounts. year. in surgeons number expansive surgeons, second growth the
patients the customers’ consumers marketing our social of to Finder ahead and supported website patient digital We implant with and surrounding season. by quarter the numerous drove media consumer shows road our busy during banner Doc that mobile
also are appreciation lower increasingly to levels the an We correction ICL as diopter diopter Their describe levels. of our decided moving the down at well the lower surgeons gaining of as goal clinical as the the advanced curve vision at improvement. ICL levels impact diopter patients of of often lower utility
future a well during China. vision longer growth higher correction. new no typically minus XXXX, which to in in range XX refractive of The corneal half during China of growth of weighted lenses Contribution performed. where ICL solution minus range China end, is sold the to unit that were for we in laser to X in a diopters second procedures To vision diopter quarter the are was XX% first more the bodes great for just accounts,
year-to-date to China half growth report up tremendous starts and refractive for compared and was the wide a While growth distributor such delighted continued of execution. a off through attributed can we market. vision This of familiarity On partnership by surgeons largest basis to ICL range successful numbers comfort lenses the are outside and in and be XXXX, and of strategic as repositioning correction, our of as premium trends ICL course a partnerships first to of growth the the outside the procedure growing prior unit primary increase using of refractive year to XX% China world’s the period.
our the discussions EVO product FDA to regulatory pipelines to market. our Turning continue the with bring we and U.S. to updates,
work when and We reviewers. will prospective and have FDA recently permitted. submitted that an to this application as appreciate FDA clinical pathway a design burdensome finalized you the must encompassing trial know be of the appropriate only information additional process least course a with reflects provide FDA’s we during We which
inaugural about of late August during like Dallas Council panel excellent, hosting affirm robust I meeting planned we where attending. U.S. will that to Surgeons education, very would remain that have be for of a dozens surgeons in and we events the podium enthusiastic an agenda
Joining business will clinical surgeons models. their ICL experience share you be surgeons leading from as will and Japan who China, Germany, and
alliance toric agreements also ICL have in additional are our approved currently lenses the ways signed recently and the in exploring broader U.S. adoption spheric accelerate Visian We to U.S. available and faster and of
performance vision spectacles. the near review that we we which near Turning for at achievement European generally the release to visual we the acuity Body, our that after of EDOF from as months or the trial and a our the announcing a of centimeters European level for DEKRA. X announcing presbyopia, trial for endpoint such XX or closed our greater reading to a approximately endpoint at and today market multi-site Notified XX lens the trial represents uncorrected submitted have primary of monocular was require of data met that issued after implanted XX/XX equal The clinical press better than XX/XX not primary XX% is separate implantation trial newspaper of to defined inches eyes. does as for
we of to implanted delighted that endpoint achieved are eyes. primary XX% report this We in
traditionally our to XX an option start a EVO up presbyopes and is While new age age age typically market includes EDOF up to opens typically XX. If myopes, very to entirely over young our lens approved, that myopic XX XX. lens for attractive
ICLs who provide of for IOLs amount also already this patients. very the cataracts. today supplemental which IOL lens of Additionally, increased presbyopia, for end could our have independence a piggyback includes implanted review, EDOF of vast focal spectacle is in large surgery our cataract getting currently or for select patients use group EDOF ICL patients as majority of And the
desire Our an provides ICL independence post the who cataract surgeon spectacle additive mono-focal surgery. elegant patients and alternative for both
where Before coming weeks. to to we financial meeting I would opportunities, call our forward look Deborah number in investment review turn over the for more community of to I the a the with performance near-term highlight of a QX, detailed like in
Cataract Meeting, become our countries in Conference year, Society investors and a Growth at attend. will acquainted European On meeting of is X, to at encourage and X, our from week, meeting Next way in the our be we European attend XXX meeting and the in investors Asian Canaccord with Last analysts surgeons Surgeons Refractive trade investors be booth more meetings during be business. Conference will Genuity show with at investors on had XX, investors experts September we This the with more outside ICL We great during Paris. Fargo ESCRS Boston. U.S. international ESCRS. for our to hosting than On Wells Healthcare September August will of with we we the Boston.
period. remarks. XXXX Baltimore, during coming on Los November we We hosting in the will host the meetings be our the my for our vision York and X, show outline to Day Investor will strategic we X-year the prepared XXXX at also XXXX, where in will planning Palace non-deal Lotte New are road Angeles weeks in Those company
call review to Deborah? financial will over I the second Deborah further results. turn quarter now to our
